Structure of Sisunatovir - syncytial virus (RSV) fusion inhibitor

oral lung penetrant RSV fusion inhibitor

Ph. II candidate (50 mg BID) for RSV infect.

opt. from literature starting point

J. Med. Chem., Mar. 17, 2021

Reviral Ltd, Hertfordshire, UK

The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.